Division of General Internal Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.
BMC Health Serv Res. 2023 Feb 21;23(1):174. doi: 10.1186/s12913-023-09128-w.
In 2019-2020, with National Cancer Institute funding, seven implementation laboratory (I-Lab) partnerships between scientists and stakeholders in 'real-world' settings working to implement evidence-based interventions were developed within the Implementation Science Centers in Cancer Control (ISC3) consortium. This paper describes and compares approaches to the initial development of seven I-Labs in order to gain an understanding of the development of research partnerships representing various implementation science designs.
In April-June 2021, members of the ISC3 Implementation Laboratories workgroup interviewed research teams involved in I-Lab development in each center. This cross-sectional study used semi-structured interviews and case-study-based methods to collect and analyze data about I-Lab designs and activities. Interview notes were analyzed to identify a set of comparable domains across sites. These domains served as the framework for seven case descriptions summarizing design decisions and partnership elements across sites.
Domains identified from interviews as comparable across sites included engagement of community and clinical I-Lab members in research activities, data sources, engagement methods, dissemination strategies, and health equity. The I-Labs use a variety of research partnership designs to support engagement including participatory research, community-engaged research, and learning health systems of embedded research. Regarding data, I-Labs in which members use common electronic health records (EHRs) leverage these both as a data source and a digital implementation strategy. I-Labs without a shared EHR among partners also leverage other sources for research or surveillance, most commonly qualitative data, surveys, and public health data systems. All seven I-Labs use advisory boards or partnership meetings to engage with members; six use stakeholder interviews and regular communications. Most (70%) tools or methods used to engage I-Lab members such as advisory groups, coalitions, or regular communications, were pre-existing. Think tanks, which two I-Labs developed, represented novel engagement approaches. To disseminate research results, all centers developed web-based products, and most (n = 6) use publications, learning collaboratives, and community forums. Important variations emerged in approaches to health equity, ranging from partnering with members serving historically marginalized populations to the development of novel methods.
The development of the ISC3 implementation laboratories, which represented a variety of research partnership designs, offers the opportunity to advance understanding of how researchers developed and built partnerships to effectively engage stakeholders throughout the cancer control research lifecycle. In future years, we will be able to share lessons learned for the development and sustainment of implementation laboratories.
在 2019-2020 年,在美国国家癌症研究所的资助下,七个实施实验室(I-Lab)合作伙伴关系在癌症控制实施科学中心(ISC3)联盟内得以发展,这些合作伙伴关系由科学家和利益相关者在“真实世界”环境中共同建立,旨在实施基于证据的干预措施。本文描述并比较了这七个 I-Lab 的初步发展方法,以了解代表不同实施科学设计的研究伙伴关系的发展情况。
在 2021 年 4 月至 6 月期间,ISC3 实施实验室工作组的成员对每个中心参与 I-Lab 发展的研究团队进行了访谈。这项横断面研究使用半结构化访谈和基于案例的方法收集和分析了关于 I-Lab 设计和活动的数据。访谈记录经过分析,确定了一系列在各站点具有可比性的领域。这些领域为七个案例描述提供了框架,总结了各站点的设计决策和伙伴关系要素。
从访谈中确定的可在各站点之间进行比较的领域包括社区和临床 I-Lab 成员在研究活动中的参与情况、数据来源、参与方法、传播策略和健康公平。I-Labs 采用各种研究伙伴关系设计来支持参与,包括参与式研究、社区参与式研究和嵌入式研究的学习卫生系统。关于数据,成员使用共同电子健康记录(EHR)的 I-Labs 既将其用作数据源,又将其用作数字实施策略。合作伙伴之间没有共享 EHR 的 I-Labs 也利用其他来源进行研究或监测,最常见的是定性数据、调查和公共卫生数据系统。所有七个 I-Labs 都使用顾问委员会或伙伴关系会议来与成员接触;六个使用利益相关者访谈和定期沟通。大多数(70%)用于吸引 I-Lab 成员的工具或方法,如顾问小组、联盟或定期沟通,都是预先存在的。智库是两个 I-Labs 开发的,代表了新颖的参与方法。为了传播研究结果,所有中心都开发了基于网络的产品,大多数(n=6)使用出版物、学习协作和社区论坛。在健康公平方面出现了重要的差异,从与服务于历史上处于边缘地位的人群的成员合作到开发新方法不等。
ISC3 实施实验室的发展代表了各种研究伙伴关系设计,为深入了解研究人员如何建立和建立伙伴关系,以便在整个癌症控制研究生命周期中有效地吸引利益相关者提供了机会。在未来几年,我们将能够分享实施实验室的发展和维持经验教训。